drugset / Trial / NCT06634589
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with separate substudies. This study currently includes four substudies, and more substudies may be added as other combination agents are identified.
Timeline
- Start
- 2024-11-27
- Primary completion
- 2028-12-02
- Completion
- 2029-12-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BGB-16673 | Other / unclassified | — | Oral |
| Subject | Glofitamab | Monoclonal antibody | — | Intravenous |
| Subject | Mosunetuzumab | Monoclonal antibody | — | Subcutaneous |
| Subject | Sonrotoclax | Other / unclassified | — | Oral |
| Subject | Zanubrutinib | Small molecule | — | Oral |
| Background | Obinutuzumab | Monoclonal antibody | — | Intravenous |